Clinical Trial

Inpatient Monitoring of Unfractionated Heparin

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Unfractionated heparin (UFH) is the most widely used intravenous (IV) anticoagulant for treating and preventing thromboembolic disease (e.g., blood clots ). UFH must be closely monitored and adjusted in the hospital. There are two assays used to monitor UFH: 1) the activated partial thromboplastin time (PTT) and 2) the chromogenic anti-factor Xa assay (anti-Xa). This study aims to compare PTT and anti-Xa methods for monitoring UFH in a pragmatic, randomized controlled trial to determine which helps patients reach a therapeutic anticoagulation range faster.
Protocol Amendment History 5 changes
notable Primary completion pushed: 2026-08 -> 2026-09 2026-08-08
minor Completion pushed: 2026-08 -> 2026-09 2026-08-08
notable Primary completion pushed: 2026-06 -> 2026-08 2026-07-22
minor Completion pushed: 2026-07 -> 2026-08 2026-07-22
notable Enrollment reduced: 2000 -> 700 participants 2026-04-21
Trial Details
NCT Number NCT06329921
Lead Sponsor Vanderbilt University Medical Center
Conditions Blood Clot, Thrombosis
Enrollment 700 participants
Start Date 2024-06-26
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-07